Versuchen GOLD - Frei
Eschewing Myopic Attitude Towards Eye Health
BioSpectrum Asia
|July 2022
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia. Thus, early intervention is crucial in the control of myopia and the onus is to be equally distributed between the stakeholders of the eye healthcare ecosystem. Studie have shown that the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. Let's explore the available early interventions that could effectively tackle the rising incidents of myopia, especially in the young.
Uncorrected myopia remains the leading cause of distance vision impairment globally, and its rising prevalence could cost billions of dollars in lost productivity in the coming decades. A hallmark study by the Brien Holden Vision Institute (BHVI) in Australia predicts that by 2050, over half the world's population or 52 per cent will be myopic.
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
Studies have shown the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia.
In particular, with quarantine practices in place during the onset of COVID-19 and children attending online classes over electronic devices, the rise in myopia has been sharp. According to a recent study, more children have developed myopia as an unexpected side-effect of the pandemic.
Diese Geschichte stammt aus der July 2022-Ausgabe von BioSpectrum Asia.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON BioSpectrum Asia
BioSpectrum Asia
India–EU FTA Paves Way for Expanded Healthcare Trade
On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India
In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Women's Health Surge in APAC
The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.
6 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer
Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
Daiichi Sankyo names Dr John Tsai as Global Head of R&D
Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"
King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
4 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
SEOUL'S RISKY DRUG PRICING RESET
Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.
2 mins
BioSpectrum Asia March 2026
BioSpectrum Asia
Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules
Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.
1 min
BioSpectrum Asia March 2026
BioSpectrum Asia
China revises drug administration regulations to spur innovation
China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.
1 min
BioSpectrum Asia March 2026
Translate
Change font size

